KLK3 and posterior cortical atrophy: This is the result for increased screening for PCa using serum prostate-specific antigen (PSA), resulting in a significant increase in the detection of low-grade PCas (Gleason ≤ 6), a disease that has been shown to pose little risk of disease progression or death [2,3,4,5].